首页> 美国卫生研究院文献>The Pan African Medical Journal >Profil épidémiologique des entérobactéries uropathogènes productrices de bêta-lactamases à spectre élargi
【2h】

Profil épidémiologique des entérobactéries uropathogènes productrices de bêta-lactamases à spectre élargi

机译:产生广谱β-内酰胺酶的尿路致病性肠杆菌的流行病学概况

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Urinary tract infections due to enterobacteria producing extended spectrum beta-lactamases (ESBL-E) constitute a infectious risk, a major therapeutic challenge and can even lead, in some cases, to a deadlock beacuse of their multi-resistance to antibiotics. This study aimed to determine the epidemiological profile of uropathogenic ESBL-E and to describe their current level of resistance to antibiotics for a better patient management according to local data. We conducted a retrospective study of all ESBL-E strains isolated from all cytobacteriogical testing of urine (CBEU) treated in the Microbiology Laboratory at the Military Hospital of Moulay Ismail, Meknes over a period of three years (from 1 January 2013 to 31 December 2015). Culture was performed according to conventional techniques and antibiogram was performed using Mueller-Hinten agar disk diffusion susceptibility test according to the recommendations from the Committee on Antimicrobial Susceptibility of the French Society for Microbiology (CA-SFM), year 2013/2014. This study allowed to report a significant overall prevalence of isolation of ESBL-E (12.2%), particularly among hospitalized patients (54.8%). The greater prevalence (72%) was registered in the Department of Urology. Among these, ESBL-E Escherichia coli constitutes the majority (61%) of the isolates, however Klebsiella pneumoniae is the major ESBL producer (25.8%) within the same species. The analysis of ESBL-E antibioresistance conducted during these three years revealed some co-resistances to ciprofloxacin (92.5%), sulfametoxazole-trimethoprim (88.4%), gentamycin (67.2%). Globally, our results are compliant with the data from the other Mediterranean countries, except for amikacin whose resistance was very low (6.1%) in our study. This study shows that the prevalence of ESBL-E in hospital is high and that its diffusion in community setting is a matter of concern. These ESBL-E are generally resistant to antibiotics, including molecules useful in urology.
机译:由于肠杆菌产生超广谱β-内酰胺酶(ESBL-E)引起的尿路感染构成传染风险,是重大的治疗挑战,在某些情况下,甚至由于它们对抗生素的多重耐药性,甚至可能导致僵局。这项研究旨在确定尿路致病性ESBL-E的流行病学特征,并描述其当前对抗生素的耐药性水平,以便根据当地数据更好地进行患者管理。我们进行了一项回顾性研究,为期三年(从2013年1月1日至2015年12月31日),该菌株是从在梅克内斯莫莱伊斯梅尔军事医院的微生物学实验室治疗的所有尿液细胞细菌学检测(CBEU)中分离的所有ESBL-E菌株进行的)。根据常规技术进行培养,并根据法国微生物学会抗菌药物敏感性委员会(CA-SFM)的建议,使用Mueller-Hinten琼脂圆盘扩散敏感性试验进行抗菌素检测,2013/2014年。这项研究报告了ESBL-E分离的总体患病率(12.2%),尤其是住院患者(54.8%)。泌尿外科的患病率更高(72%)。在这些菌株中,ESBL-E大肠杆菌占大多数(61%),但同一物种中肺炎克雷伯菌是主要的ESBL产生者(25.8%)。在这三年中对ESBL-E的抗药性进行了分析,结果显示对环丙沙星(92.5%),磺胺甲唑-甲氧苄氨嘧啶(88.4%),庆大霉素(67.2%)有一些抗药性。在全球范围内,我们的结果与其他地中海国家的数据相符,但丁胺卡那霉素的耐药性非常低(6.1%)。这项研究表明,ESBL-E在医院中的患病率很高,并且其在社区环境中的扩散令人担忧。这些ESBL-E通常对抗生素具有抗性,包括可用于泌尿科的分子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号